Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.

ABSTRACT: While interest in immunotherapies is renewed by the successful introduction of immune checkpoint blocking agent in the clinic, advances in genome sequencing are opening new possibilities in the design of increasingly personalized vaccines. Personalization of medicine can now be realistically contemplated at the single patient level. Unlike the previous generation of cancer vaccines, neoantigen directed vaccines would target truly specific tumor antigens resulting from acquired tumor genome mutations. Immune response induced by this next generation vaccine would not be subject to self-tolerance and will likely result to enhanced efficacy. Nevertheless, this new technologies can hold to their promises only if sponsors manage to meet several scientific, technical, logistical and regulatory ch

SUBMITTER: Bendjama K 

PROVIDER: S-EPMC5612284 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature